Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.
Xilio was founded in 2016 and is headquartered in Waltham, Mass. For more information, please visit www.xiliotx.com
• Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors
• Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic
• Two investigational new drug (IND) applications planned in 2021
2020/11/12Xilio Therapeutics today announced the presentation of preclinical data of its lead investigational therapies at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SICT 2020).
2020/07/23Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry
To Lead XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA-4) into the Clinic while Xilio Continues to Advance its Tumor-Selective Cytokine Pipeline
